Global Migraine Trends Analysis
Posted on December 11 2024,

https://doi.org/10.1007/s40122-024-00690-7
Key Terms Explained:
- ASPR (Age-Standardized Prevalence Rate): Number of cases per 100,000 people, adjusted for age differences in populations
- EAPC (Estimated Annual Percentage Change): How fast the rate is changing year over year
- DALYs (Disability-Adjusted Life Years): Years of healthy life lost due to disability and early death
- SDI (Sociodemographic Index): Measure of a region's development level (0-1 scale)
Table 1: Basic Numbers - How Big is the Problem?
What We're Measuring | 1990 | 2021 | Change | What This Means |
---|---|---|---|---|
Total People Affected | 732.56 million | 1.16 billion | +58.15% | About 1 in 7 people now have migraine |
New Cases Per Year | 63.50 million | 90.18 million | +42.06% | More new cases being diagnosed yearly |
Impact on Life (DALYs) | 27.41 million | 43.38 million | +58.27% | Increasing impact on quality of life |
Table 2: Men vs. Women - Who's More Affected?
Measurement | Women (2021) | Men (2021) | What This Tells Us |
---|---|---|---|
Number of Cases | 725.24 million | 433.19 million | Women are more affected overall |
Rate per 100,000 (ASPR) | 17,902.6 | 10,624.2 | Higher prevalence in women |
Growth Rate (EAPC) | 0.02 | 0.13 | Men's cases growing 6.5x faster! |
Table 3: Age Patterns - When Does Migraine Occur?
Age Group | What We See | Why It Matters |
---|---|---|
10-14 years | Highest new cases (2,368.93 per 100,000) | Critical age for first onset and intervention |
30-34 years | Most total cases (128.09 million) | Major impact during peak working years |
40-44 years | Highest overall rate (21,579.93 per 100,000) | Greatest burden during mid-career |
Table 4: Geographic Differences - Where's the Problem Worst?
Development Level | Rate per 100,000 | Trend | What This Means |
---|---|---|---|
High SDI (Most Developed) | 15,365.14 | Stable | Better diagnosis but rates leveling off |
Medium SDI | 14,200.50 | Rising Fast | Improving detection and reporting |
Low SDI (Least Developed) | 12,808.97 | Little Change | Possible underdiagnosis due to limited healthcare |
Overall Study Implications
- Healthcare systems need to improve migraine detection in men
- Early intervention programs needed for adolescents
- Workplace support crucial during peak working years
- Developing regions need better access to migraine care
- Global burden expected to continue rising through 2050
Sat, Apr 26, 25
Migraine Pharmaceutical Treatment Pearls
Comprehensive expert guide to migraine treatments: evidence-based recommendations for acute medications (NSAIDs, triptans, gepants), preventive therapies, and special considerations for pregnancy, cardiovascular disease, and other medical conditions. Find effective strategies...
Read MoreFri, Apr 25, 25
Evidence-Based Guidelines for the Pharmacological Treatment of Migraine (Updated April 2025)
Discover evidence-based guidelines for migraine treatment from leading experts. Learn about effective medications for acute attacks and prevention, their evidence quality, and recommendation strength to better manage your migraines.
Read MoreThu, Apr 24, 25
Clinical Predictors for Efficacy of Erenumab (Aimovig) for Migraine
Discover key predictors of Aimovig (erenumab) response in migraine patients. This REFORM study reveals which patients benefit most from CGRP therapy and why timing matters. Evidence-based insights for better treatment...
Read More